© 2019 Genprex Inc. All Rights Reserved.
Our platform technologies are designed to administer cancer fighting tumor suppressor genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
We are developing our lead product candidate, Oncoprex™ immunogene therapy, to be administered in combination with targeted therapies and immunotherapies for non-small cell lung cancer. Preclinical research indicates that Oncoprex might also be effective in fighting other types of cancer and we are exploring its use in other cancer types.
We are a multidisciplinary team with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
At Genprex, we are committed to pioneering a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
Genprex announced today the appointment of John N. Bonfiglio, PhD, to the company’s Board of Directors.
Noble Capital Markets’ Fifteenth Annual Investor / Equity Conference
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 3, 2019– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019.
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019.
We’re passionate about the work we’re doing to revolutionize the fight against cancer, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.